Sermonix also has a Scientific Advisory Board that includes experts in the fields of osteoporosis and VVA.

 

David Archer, MD—Professor in the Department of Obstetrics and Gynecology at Eastern Virginia Medical School in Norfolk, Virginia. In addition he is the Director of the Clinical Research Center located in the Jones Institute for Reproductive Medicine, Norfolk, Virginia. Research interests in management and etiology of abnormal uterine bleeding and menopausal symptoms, and steroid metabolism.

 

Felicia Cosman, MD—Medical Director, Clinical Research Center, Helen Hayes Hospital, Professor of Clinical Medicine Columbia University, NYC. Endocrinologist, osteoporosis specialist and principal investigator of numerous fracture prevention trials.

 

Steven Cummings, MD— Director, CPMC Research Institute and the University of California Department of Epidemiology and Biostatistics. Emeritus Professor of Medicine, Epidemiology and Biostatistics, and Associate Chair for Clinical Research at the University of California, San Francisco. Osteoporosis expert and lead author of PEARL fracture prevention results in New England Journal of Medicine.

 

Steven Goldstein, MD—Professor, Department of Obstetrics and Gynecology, New York University, NYC. Clinical and research interest in endometrial ultrasound, osteoporosis. Dr Goldstein was lead author of the PEARL trial endometrial safety paper and presented the data at the lasofoxifene FDA Advisory Committee meeting in 2008. He co-authored the paper on PEARL fracture reduction.

 

Sheryl Kingsberg, PhD—Division Chief, OB/GYN Behavioral Medicine, Professor of Psychiatry, University Hospitals, Case Western Reserve, Cleveland OH. Research and clinical interests in VVA and female sexual dysfunction.

 

Andrea LaCroix, PhD—Professor of Epidemiology, UCSD, San Diego CA, specializes in the health of postmenopausal and older women, Principal Investigator and author on the effects of lasofoxifene on breast cancer incidence, cardiovascular events and fractures in women with osteoporosis.

 

Michael Lincoff, MD— Vice-Chair, Department of Cardiovascular Medicine, Director, Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, OH

 

James Liu, MD—Chairman and Professor, Department of Obstetrics and Gynecology University Hospitals, Case Western Reserve, Cleveland OH. Expertise in reproductive endocrinology and menopause.

 

Donald McDonnell PhD—Glaxo-Wellcome Professor of Molecular and Cell Biology and Chairman Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina. Expert in estrogen receptor biology, cancer prevention and treatment research, and involved in the early discovery and development of lasofoxifene while at Ligand.

 

Michael McClung, MD—Director, Oregon Osteoporosis Center, Portland OR. Endocrinologist with expertise in osteoporosis and metabolic bone disease. A lasofoxifene investigator and author of trial results on lasofoxifene osteoporosis prevention compared to raloxifene.

 

James Simon, MD—Clinical Professor of Obstetrics and Gynecology at George Washington University, Washington DC. Expert in gynecological and sexual health, leading clinical researcher, author of numerous publications on SERMS, estrogen, menopause, VVA and sexual dysfunction.

 

Sermonix External Agency Partners

Sermonix also engages external leading legal counsel on biotech regulatory, licensing and patent law from the firms of Dechert LLP, and Hyman, and Phelps LLP, both of Washington DC, and Fenwick and West LLP of Mountainview California—all part of a team helping to navigate the path to successful approval and commercialization. The team has negotiated favorable licensing agreements with Ligand and Duke. New IP could potentially have exclusivity out to 2037.